-
03:23:54 PM

EPIX Stock News

09/18/23 7:00 AM
Nasdaq : EPIX
clinical trial
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Recommended Phase 2 dose regimen identified as masofaniten 600 mg BID combined with enzalutamide 160 mg QD. SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Sept. 18, 2023/ PRNewswire/- ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the initiation of the...
RHEA-AI
neutral
08/08/23 7:00 AM
Nasdaq : EPIX
earnings
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi ® expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study. SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 8, 2023/ PRNewswire/- ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the...
RHEA-AI
neutral
05/09/23 7:00 AM
Nasdaq : EPIX
earnings
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
Entered into clinical trial support agreement with Janssen to supply Erleada ® and Zytiga ® for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2 H2023. SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 9, 2023/ PRNewswire/- ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on...
RHEA-AI
neutral
04/12/23 7:00 AM
Nasdaq : EPIX
clinical trial
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023/ PRNewswire/- ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement with Janssen Research& Development, LLC to enable evaluation...
RHEA-AI
very positive
03/09/23 7:30 AM
Nasdaq : SMMT, EPIX, PBYI
earnings
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Summit Therapeutics Inc. today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022. Akeso retained development and commercialization rights for the rest of the world, including China. In exchange for these rights, Summit committed to an upfront payment of $500 million to be...
RHEA-AI
positive